FP10 POM

Please see the urinary catheterisation in adults document CG/070/18 which can be found on the Cornwallft intranet page.

Papulopustular rosacea - discontinue if no improvement after 1 month

May be prescribed for patients unable to take a PPI

May be prescribed for patients unable to take a PPI

Consider Dymista as a third line drug in seasonal allergy after patients have tried an oral antihistamine and a topical steroid for about a month

To be prescribed only under the advice of a dietitian

To be prescribed only under the advice of a dietitian

To be prescribed only under the advice of a dietitian

To be prescribed only under the advice of a dietitian

To be prescribed only under the advice of a dietitian

To be prescribed only under the advice of a dietitian

To be prescribed only under the advice of a dietitian

Fiasp (Fast acting insulin aspart) for patients 1 year and over under the care of the paediatric diabetes service, who are either unpredictable eaters or have problematic post-meal glucose rise, not managed with dietetic input and assessed as competent to try Fiasp by the dietician.

Moderate Potency

Fiasp (Fast acting insulin aspart) for patients 1 year and over under the care of the paediatric diabetes service, who are either unpredictable eaters or have problematic post-meal glucose rise, not managed with dietetic input and assessed as competent to try Fiasp by the dietician.

Fiasp (Fast acting insulin aspart) for patients 1 year and over under the care of the paediatric diabetes service, who are either unpredictable eaters or have problematic post-meal glucose rise, not managed with dietetic input and assessed as competent to try Fiasp by the dietician.

Antimetabolites
For actinic keratosis for areas up to 500cm2 and for Bowen's disease. Additional information may be found on Cornwall RMS

adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older

Commissioned for all people (both adults and children) with type 1 diabetes who have been assessed by their specialist to meet the prevailing CIOS ICB criteria. This product will be replacing the Freestlye Libre 2 from July 2024. Please note this is a 15 day sensor

Second line choice for patients with COPD and bronchiectasis following a request from the specialist respiratory physiotherapy team.

Only to be prescribed in primary care following a request from the RCHT diabetes team for people with type 1 diabetes alongside the mylife Ypsopump and CamAPS FX (MyLife) algorithm as part of a hybrid closed loop (HCL) system. May also be requested by secondary care teams for use as part of a hybrid closed-loop system in pregnancy in line with NICE TA943. Not to be prescribed as a standalone CGM. This product will be replacing the freestyle libre 3 from Dec 2025. Please note this is a 15 day sensor.

Moderate Potency

adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older

adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older

adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older

adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older

adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older

For type 1 paediatric patients who are unable to use a separate ketone meter.